Kengreal, Kengrexal(cangrelor)
Kengreal, Kengrexal (cangrelor) is a small molecule pharmaceutical. Cangrelor was first approved as Kengrexal on 2015-03-23. It has been approved in Europe to treat acute coronary syndrome and vascular surgical procedures. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target P2Y purinoceptor 13 and uracil nucleotide/cysteinyl leukotriene receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Kengreal
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cangrelor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KENGREAL | Chiesi Farmaceutici | N-204958 RX | 2015-06-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kengreal | New Drug Application | 2020-09-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| C9460 | Injection, cangrelor, 1 mg |
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | 3 | 5 | — | 9 | |
| St elevation myocardial infarction | D000072657 | — | 1 | — | 7 | 1 | 9 | ||
| Coronary artery disease | D003324 | I25.1 | — | 3 | — | 3 | 2 | 8 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | 2 | 1 | 4 |
| Percutaneous coronary intervention | D062645 | — | — | 1 | 1 | 1 | 3 | ||
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | — | 1 | — | 1 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | 1 | — | 1 |
| Induced hypothermia | D007036 | — | — | — | 1 | — | 1 | ||
| Out-of-hospital cardiac arrest | D058687 | — | — | — | 1 | — | 1 | ||
| Cardiogenic shock | D012770 | R57.0 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 2 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-st elevated myocardial infarction | D000072658 | — | — | — | — | 1 | 1 | ||
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CANGRELOR |
| INN | cangrelor |
| Description | Cangrelor is a nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries. It has a role as a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a nucleoside triphosphate analogue, an organofluorine compound, an aryl sulfide, an organochlorine compound, a secondary amino compound and an adenosine 5'-phosphate. It is a conjugate acid of a cangrelor(4-). |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 163706-06-7 |
| RxCUI | 1656052 |
| ChEMBL ID | CHEMBL334966 |
| ChEBI ID | — |
| PubChem CID | 9854012 |
| DrugBank | DB06441 |
| UNII ID | 6AQ1Y404U7 (ChemIDplus, GSRS) |
Target
Agency Approved
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Alternate
P2RY13
P2RY13
GPR17
GPR17
Organism
Homo sapiens
Gene name
P2RY13
Gene synonyms
GPR86, GPR94
NCBI Gene ID
Protein name
P2Y purinoceptor 13
Protein synonyms
G protein-coupled receptor 86, G-protein coupled receptor 86, G-protein coupled receptor 94, purinergic receptor P2Y, G-protein coupled, 13
Uniprot ID
Mouse ortholog
P2ry13 (74191)
P2Y purinoceptor 13 (Q9D8I2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,183 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,557 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more